Author: Bein, Thomas; Grasso, Salvatore; Moerer, Onnen; Quintel, Michael; Guerin, Claude; Deja, Maria; Brondani, Anita; Mehta, Sangeeta
Title: The standard of care of patients with ARDS: ventilatory settings and rescue therapies for refractory hypoxemia Document date: 2016_4_4
ID: krpg9u1u_37
Snippet: Tracheobronchial secretion should be investigated using quantitative BAL (100-120 ml 0.9 % NaCl) or mini-non-bronchoscopic BAL (20-40 ml 0.9 % NaCl), especially in (hypoxemic) situations were bronchoscopyguided BAL might be too invasive [63] . The cutoff for significant number of colony forming units to differentiate between colonization and infection depends on the diagnostic test: tracheobronchial secretion, 10-5 CFU/ ml; BAL, 10-4 CFU/ml; and .....
Document: Tracheobronchial secretion should be investigated using quantitative BAL (100-120 ml 0.9 % NaCl) or mini-non-bronchoscopic BAL (20-40 ml 0.9 % NaCl), especially in (hypoxemic) situations were bronchoscopyguided BAL might be too invasive [63] . The cutoff for significant number of colony forming units to differentiate between colonization and infection depends on the diagnostic test: tracheobronchial secretion, 10-5 CFU/ ml; BAL, 10-4 CFU/ml; and protected specimen brush, 10-3 CFU/ml [64] . Gram-staining is still recommended, since in patients without anti-infective treatment a high negative predictive value is documented. For exclusion of atypical pneumonia, Legionella antigen assessment (urine, sputum) with two negative tests is recommended. New molecular assays as part of a panel for viral pneumonia (influenza A with two subtypes, parainfluenza 1-4) and atypical pathogens with a short run time are available. In ICU patients with influenza-associated pneumonia at risk for bacterial co-infections, a 5-day delay for treatment of seasonal influenza and influenza-associated infection is reported (Table 3 ) [65] . Of note careful examination may help to exclude some clinical entities that are mistaken for ARDS (e.g., idiopathic pulmonary fibrosis, cryptogenic organizing pneumonia, nonspecific interstitial pneumonitis, Wegener's granulomatosis, or acute eosinophilic pneumonia). These diseases need of course a lung-protective strategy (limitation of V T ), but some other ARDS-specific measures as addressed in this article are not proven and may not be "automatically" helpful [66, 67] . Various diagnostic tools of BAL analysis (hemogram, cytology, and flow cytometric analysis) have been described as a complete diagnostic workup [68] . In immunosuppressed patients specific diagnostic and therapeutic procedures are essential. Pretreatment with antiinfectives, local resistance, and severity of illness with organ failure have to be considered for calculated use of broad-spectrum antibiotics [69] . Targeted treatment after successful detection of the responsible pathogen is more effective and lowers mortality. Moreover, de-escalation and targeted anti-infective treatment of pneumonia reduce superinfection with resistant pathogens.
Search related documents:
Co phrase search for related documents- anti infective treatment and atypical pneumonia: 1
- anti infective treatment and broad spectrum: 1
- anti infective treatment and clinical entity: 1
- atypical pathogen and bacterial co infection: 1
- atypical pathogen and clinical entity: 1
- atypical pathogen and co infection: 1, 2, 3
- atypical pneumonia and bacterial co infection: 1, 2, 3
- atypical pneumonia and broad spectrum: 1, 2, 3, 4, 5, 6
- atypical pneumonia and broad spectrum antibiotic: 1
- atypical pneumonia and clinical entity: 1, 2, 3
- atypical pneumonia and co infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- bacterial co infection and broad spectrum: 1, 2, 3
- bacterial co infection and broad spectrum antibiotic: 1, 2
- bacterial co infection and co infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- bacterial co infection risk and co infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
- BAL analysis and broad spectrum: 1
- broad spectrum and careful examination: 1
- broad spectrum and clinical entity: 1
- broad spectrum and co infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
Co phrase search for related documents, hyperlinks ordered by date